Online Inquiry
Inquiry
AT9283
| Product Name: | AT9283 |
| CAT#: | DEERD-2312-LGZ-2 |
| Package: | 5mg/10mg/25mg/100mg/10mM * 1mL in DMSO |
| Datasheet |
Description
AT9283 inhibits aurora kinase A and B and targets other tyrosine and serine/threonine kinases that are associated with myeloid cell proliferation.
Basic Information
| Application: | Aurora/JAK Inhibitor |
| CAS Number: | 896466-04-9 |
| Formula: | C19H23N7O2 |
| Molecular Weight: | 381.4 |
| SMILES: | C1CC1NC(=O)NC\2=CNN/C2=C\3/N=C4C=CC(=CC4=N3)CN5CCOCC5 |
| Solubility-In vitro: | In vitro (25°C): DMSO: 68 mg/mL (178.28 mM) Water: Insoluble Ethanol: 34 mg/mL (89.13 mM) |
| Solubility-In vivo: | 2% DMSO+30% PEG 300+ddH2O: 4 mg/mL |
Target Info
| JAK3: IC50: | 1.1nM |
| JAK2: IC50: | 1.2nM |
| AuroraA: IC50: | ~3.0nM |
| AuroraB: IC50: | ~3.0nM |
| Abl1(T315I): IC50: | 4nM |
| GSK-3β: IC50: | 1nM-10nM |
| FGFR2: IC50: | 1-10nM |
| VEGFR3/FLT4: IC50: | 1nM-10nM |
| Mer: IC50: | 1nM-10nM |
| RET: IC50: | 1nM-10nM |
| RSK2: IC50: | 1nM-10nM |
| RSK3: IC50: | 1nM-10nM |
| TYK2: IC50: | 1nM-10nM |
| YES: IC50: | 1nM-10nM |
| Abl(Q252H): IC50: | 10nM-30nM |
| DRAK1: IC50: | 10nM-30nM |
| FGFR1: IC50: | 10nM-30nM |
| FGFR1(V561M): IC50: | 10nM-30nM |
| FGFR2(N549H): IC50: | 10nM-30nM |
| FGFR3: IC50: | 10nM-30nM |
| VEGFR1/FLT1: IC50: | 10nM-30nM |
| FLT3: IC50: | 10nM-30nM |
| PDGFRα(D842V): IC50: | 10nM-30nM |
| PDK-1: IC50: | 10nM-30nM |
| PKCμ: IC50: | 10nM-30nM |
| RSK4: IC50: | 10nM-30nM |
| Src(T341M): IC50: | 10nM-30nM |
| VEGFR2: IC50: | 10nM-30nM |
Storage
|
Preparing Stock Solutions
|
0.1 mM_1 mg: 26.22 mL
0.1 mM_5 mg: 131.1 mL
0.1 mM_10 mg: 262.19 mL
0.5 mM_1 mg: 5.24 mL
0.5 mM_5 mg: 26.22 mL
0.5 mM_10 mg: 52.44 mL
1 mM_1 mg: 2.62 mL
1 mM_5 mg: 13.11 mL
1 mM_10 mg: 26.22 mL
5 mM_1 mg: 0.52 mL
5 mM_5 mg: 2.62 mL
5 mM_10 mg: 5.24 mL
|
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
